SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Drayson, M. Articles by Bradwell, A. R. Search for Related Content PubMed PubMed Citation Articles by Drayson, M. Articles by Bradwell, A. R. Related Collections Neoplasia Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 May 2001, Vol. 97, No. 9, pp. 2900-2902 BRIEF REPORT Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma Mark Drayson, Lian X. Tang, Roger Drew, Graham P. Mead, Hugh Carr-Smith, and Arthur R. Bradwell From the Department of Immunology, The Medical School, University of Birmingham, Birmingham, England, and The Binding Site, Birmingham, England.     Abstract Top Abstract Introduction Study design Results and discussion References Using sensitive, automated immunoassays, increased concentrations of either  or  free light chains (and abnormal / ratios) were detected in the sera of 19 of 28 patients with nonsecretory multiple myeloma. Four other patients had suppression of one or both light chains, and the remaining 5 sera had normal or raised free light-chain concentrations with substantially normal / ratios. Six of the patients with an elevated single free light chain, who were studied during follow-up, had changes in disease activity that were reflected by the changes in free light-chain concentrations. It is concluded that quantification of free light chains in serum should prove useful for the diagnosis and monitoring of many patients with nonsecretory myeloma. (Blood. 2001;97:2900-2902) © 2001 by The American Society of Hematology.     Introduction Top Abstract Introduction Study design Results and discussion References Nonsecretory multiple myeloma (NSM) is characterized by the absence of detectable monoclonal proteins in serum and urine and accounts for 1% to 5% of all patients with multiple myeloma.1 In approximately 85% of patients with NSM, immunohistochemical studies demonstrate the presence of cytoplasmic M-proteins within the plasma cells of the bone marrow indicating immunoglobulin synthesis.2 Using sensitive techniques, monoclonal free light chains (flc) can be detected in the urine of some of these patients,2 but the usual serum and urine electrophoretic assays are inadequate.3 Thus, the diagnosis and monitoring of patients with NSM depends on clinical assessment and bone marrow biopsies. This study evaluated the use of sensitive, serum flc immunoassays in the diagnosis and management of patients with NSM.     Study design Top Abstract Introduction Study design Results and discussion References Collection and storage of serum from patients with NSM We obtained archived sera from patients studied in the United Kingdom, Medical Research Council, Myeloma Trials between 1983 and 1999. From a total of 2323 patients, 64 (3.6%) had NSM of which 28 were selected for study because of complete clinical data and adequate serum samples. The clinical diagnosis of multiple myeloma was based on the plasma cell content of bone marrow aspirates or trephine biopsies together with the clinical features of multiple myeloma, including lytic bone lesions or fractures. At the time of diagnosis, none of the patients were considered to have significant monoclonal proteins in their serum or urine (3 had minimal monoclonal urine flc; Table 1) by the routine laboratory tests. These comprised analysis of serum and urine by electrophoresis together with immunoelectrophoresis or immunofixation electrophoresis (IFE). Six of the 28 patients were further studied to assess the role of flc assays for disease monitoring. In these individuals, flc were measured in sera collected at presentation, plateau phase (asymptomatic, stable hemoglobin, and normal serum 2-microglobulin) and at relapse, each phase having been established by the clinical features and bone marrow biopsies. All sera had been stored, long-term, at 20°C with sodium azide as preservative.                                View this table: [in this window] [in a new window]   Table 1. Serum free light-chain concentrations in 28 patients with nonsecretory myeloma Immunoassays for measuring free  and free  light chains The flc were measured using latex-enhanced, immunoassays4 on a Behring nephelometric analyzer (Dade Behring, Deerfield, IL). These quantitative assays could detect less than 1.0 mg/L  and  compared with 150 to 500 mg/L by IFE and 500 to 2000 mg/L by serum protein electrophoresis.4,5 Calibration was against purified flc that had been quantified by amino acid analysis.6 Results were compared with 100 normal (blood donor) sera in which the mean concentration of free  was 8.4 mg/L and free , 14.5 mg/L, with a mean / ratio of 0.6 (range, 0.36-1.0). Because IFE techniques have improved since the patients first presented, all sera were tested by IFE at 1:2 dilution against whole  and  antisera and neat by IFE against free  and  antisera. No urine specimens were available for evaluation. An assessment of flc molecular weight was made on sera from patients 5 and 7 by subjecting them to size separation chromatography on Sephadex G100 (Amersham Pharmacia Biotech, Little Chalfont, United Kingdom) and polyacrylamide gel electrophoresis (PAGE) using reducing and nonreducing gels. Sera from patients 1, 3, 5, 7, and 8 were assessed by immunodiffusion in agarose gels against antisera specific for IgGFc, whole  and free  to confirm the presence of flc.     Results and discussion Top Abstract Introduction Study design Results and discussion References Table 1 shows the serum flc concentrations from the 28 patients together with the / concentration ratios, the bone marrow plasma cell content at clinical presentation, and other positive laboratory results. In 19 of the sera, concentrations of either  or  were highly elevated and / concentration ratios were abnormal with 6 having suppression of the other light chain. On the basis of increased serum flc levels these patients could be classified as oligosecretory myelomas.1 Four other patients had suppression of one or both flc with little evidence of light-chain clonality. The remaining 5 samples had normal/borderline / ratios of which 2 contained elevated concentrations and 3, normal concentrations of both flc. Presumably, some of these patients truly have nonproducer myelomas, but we have no immunohistochemical data on bone marrow plasma cells to confirm this suggestion. These results compare with 15% nonproducer myelomas reported in immunohistochemical studies.1 The 6 patients studied during the course of their disease (5  and 1 ) showed changes in concentrations of flc that were in accordance with their clinical progress (Figure 1). In patient 2 an increase of flc concentrations occurred before the patient was judged to have relapsed by the existing clinical criteria. View larger version (18K): [in this window] [in a new window]   Figure 1. Changes in serum flc concentrations and clinical status in 6 patients with NSM. NR indicates upper limit of normal range; numbers refer to patients in Table 1. Table 1 shows that some of the samples with high flc concentrations were weakly positive when reassessed by sensitive IFE. The monoclonal bands detected in the 4 -producing myelomas were weak and diffuse, whereas the bands in 3 -producing myelomas were narrow and clearly visible by IFE using flc-specific antibodies. In the other patients with a single elevated flc, no monoclonal bands were detected by IFE even though the concentrations measured by nephelometry were much greater than the detection limit of IFE (~100 mg/L). When 5 of these samples were further analyzed by gel immunodiffusion, all contained substantial amounts of flc (seen as immunoprecipitation nonidentity lines between IgGFc and flc antisera), although the amounts could not be quantified in these assays. Samples 5 and 7 were investigated for polymerized light chains. Sample 5 contained  immunoreactivity at sizes ranging from 40 to 200 kd with peaks at approximately 42 kd, 96 to 107 kd, and 200 kd by chromatography and PAGE but none at 25 kd (monomeric flc). Sample 7 contained large molecular weight free  light chains at 150 to 200 kd but little at lower molecular weights. Thus, these 2 representative sera contained variably polymerized flc, which may be structurally abnormal, as previously suggested.7 The polymerization could account for the diffuse immunoprecipitation observed with most of the samples by IFE. Such large polymers would have minimal renal clearance compared with monomeric flc and this could account for the negative flc urine tests in NSM. In addition, the more frequent occurrence of diffuse IFE bands in the  NSM indicates that variable polymerization is more common than for  NSM and could account for the 4:1 ratio of / NSM that is reported in the literature.1 Table 1 shows the concentrations and ranges of flc in normal sera. These results were obtained from individuals who were younger (18-54 years) than the patients and indicates that an age-matched control group is required for future studies. It is of note that the normal flc concentrations (which were based on standardization against pure proteins6) showed  values lower than  values. Most investigations have recorded the inverse, but higher normal  levels were reported in a recent study.8 Although there are approximately twice the number of -producing compared with -producing plasma cells in the body,  is normally monomeric (25 kd), whereas  is largely dimeric (50 kd) and is cleared more slowly by the kidney. In a study on the clearance of dextran polymers, it was shown that molecules of 20 kd were cleared 3.2 times faster than 37-kd molecules.9 The slower clearance of  molecules might partly explain the inverse serum / ratio that was observed. The assays described here do not measure the absolute amount of flc present in the sera and no accurate reference method is available. It is possible that the nephelometric immunoassays overestimate the true concentrations. Polymers of flc containing multiple epitopes could enhance the kinetics of immunoprecipitation resulting in relatively high results compared with the same concentrations of monomeric flc. A more complete analysis of these issues will be the subject of further studies. Nevertheless, the results from the current study indicate that the sensitive quantification of serum flc should prove useful for the diagnosis and monitoring of many patients with NSM.     Acknowledgments We thank The Binding Site for the provision of the immunoassay kits. The myeloma sera were provided by the MRC Adult Leukaemia Working Party.     Footnotes Submitted July 24, 2000; accepted December 20, 2000. Supported in part by a grant from the Department of Trade and Industry (grant no. WMR/26799/SP). The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: A. R. Bradwell, Division of Immunity and Infection, The Medical School, University of Birmingham, Birmingham B15 2TT, England.     References Top Abstract Introduction Study design Results and discussion References 1. Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma and plasma cell leukemia. Hematol Oncol Clin North Am. 1999;13:1259-1272[CrossRef][Medline] [Order article via Infotrieve]. 2. Turesson I, Grubb A. Non-secretory or low-secretory myeloma with intracellular kappa chains. Acta Med Scand. 1978;204:445-451[Medline] [Order article via Infotrieve]. 3. Sheehan T, Sinclair D, Tansey P, O'Donnell JR. Demonstration of serum monoclonal immunoglobulin in a case of non-secretory myeloma by immunoisoelectric focusing. J Clin Pathol. 1985;38:806-809[Abstract/Free Full Text]. 4. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001. In press. 5. Keren DF. Proteins in serum identified by high-resolution electrophoresis High-Resolution Electrophoresis and Immunofixation, 2nd ed.: Butterworth-Heinemann; 1994:41-89. 6. Carr-Smith HD, Edwards J, Showell P, Drew R, Tang L, Bradwell AR. Preparation of an immunoglobulin free-light chain reference material. Clin Chem. 2000;46:A180. 7. Diemert MC, Musset L, Gaillard O, et al. Electrophoretic study of the physico-chemical characteristics of Bence-Jones proteinuria and its association with kidney damage. J Clin Pathol. 1994;47:1090-1097[Abstract/Free Full Text]. 8. Abe M, Goto T, Kosaka M, Wolfenbarger D, Weiss DT, Solomon A. Differences in kappa and lambda (:) ratios of serum and urinary free light chains. Clin Exp Immunol. 1998;111:457-462[CrossRef][Medline] [Order article via Infotrieve]. 9. Arfors K-E, Rutili G, Svensjö E. Microvascular transport of macro-molecules in normal and inflammatory conditions. Acta Physiol Scand Suppl. 1979;463:93-103. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H.-T. Tsai, N. E. Caporaso, R. A. Kyle, J. A. Katzmann, A. Dispenzieri, R. B. Hayes, G. E. Marti, M. Albitar, P. Ghia, S. V. Rajkumar, et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study Blood, December 3, 2009; 114(24): 4928 - 4932. [Abstract] [Full Text] [PDF] J.-L. Harousseau, M. Attal, and H. Avet-Loiseau The role of complete response in multiple myeloma Blood, October 8, 2009; 114(15): 3139 - 3146. [Abstract] [Full Text] [PDF] R. B Fulton and S. L Fernando Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy Ann Clin Biochem, September 1, 2009; 46(5): 407 - 412. [Abstract] [Full Text] [PDF] D. F. Keren Heavy/Light-Chain Analysis of Monoclonal Gammopathies Clin. Chem., September 1, 2009; 55(9): 1606 - 1608. [Full Text] [PDF] M. M. Giarin, L. Giaccone, R. Sorasio, C. Sfiligoi, B. Amoroso, F. Cavallo, A. Cipriani, A. Palumbo, and M. Boccadoro Serum Free Light Chain Ratio, Total {kappa}/{lambda} Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Clin. Chem., August 1, 2009; 55(8): 1510 - 1516. [Abstract] [Full Text] [PDF] J. A. Katzmann, R. A. Kyle, J. Benson, D. R. Larson, M. R. Snyder, J. A. Lust, S. V. Rajkumar, and A. Dispenzieri Screening Panels for Detection of Monoclonal Gammopathies Clin. Chem., August 1, 2009; 55(8): 1517 - 1522. [Abstract] [Full Text] [PDF] S. Singhal, E. Vickrey, J. Krishnamurthy, V. Singh, S. Allen, and J. Mehta The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios Blood, July 2, 2009; 114(1): 38 - 39. [Abstract] [Full Text] [PDF] E. J.D. Robson, J. Taylor, C. Beardsmore, S. Basu, G. Mead, and T. Lovatt Utility of Serum Free Light Chain Analysis When Screening for Lymphoproliferative Disorders: The Experience at a District General Hospital in the United Kingdom Lab Med, June 1, 2009; 40(6): 325 - 329. [Full Text] [PDF] D. Siegel, E. Bilotti, and K. H. van Hoeven Serum Free Light Chain Analysis for Diagnosis, Monitoring, and Prognosis of Monoclonal Gammopathies Lab Med, June 1, 2009; 40(6): 363 - 366. [Abstract] [Full Text] [PDF] O. Landgren, R. A. Kyle, R. M. Pfeiffer, J. A. Katzmann, N. E. Caporaso, R. B. Hayes, A. Dispenzieri, S. Kumar, R. J. Clark, D. Baris, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study Blood, May 28, 2009; 113(22): 5412 - 5417. [Abstract] [Full Text] [PDF] J. M. Abadie, K.H. van Hoeven, and J. M. Wells Are Renal Reference Intervals Required When Screening for Plasma Cell Disorders With Serum Free Light Chains and Serum Protein Electrophoresis? Am J Clin Pathol, February 1, 2009; 131(2): 166 - 171. [Abstract] [Full Text] [PDF] J. A. Katzmann and A. Dispenzieri Screening Algorithms for Monoclonal Gammopathies Clin. Chem., November 1, 2008; 54(11): 1753 - 1755. [Full Text] [PDF] A. P. Piehler, N. Gulbrandsen, P. Kierulf, and P. Urdal Quantitation of Serum Free Light Chains in Combination with Protein Electrophoresis and Clinical Information for Diagnosing Multiple Myeloma in a General Hospital Population Clin. Chem., November 1, 2008; 54(11): 1823 - 1830. [Abstract] [Full Text] [PDF] A. Dispenzieri, L. Zhang, J. A. Katzmann, M. Snyder, E. Blood, R. DeGoey, K. Henderson, R. A. Kyle, M. M. Oken, A. R. Bradwell, et al. Appraisal of immunoglobulin free light chain as a marker of response Blood, May 15, 2008; 111(10): 4908 - 4915. [Abstract] [Full Text] [PDF] N. C. Munshi Investigative Tools for Diagnosis and Management Hematology, January 1, 2008; 2008(1): 298 - 305. [Abstract] [Full Text] [PDF] S. Singhal, R. Stein, E. Vickrey, and J. Mehta The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias Blood, April 15, 2007; 109(8): 3611 - 3612. [Full Text] [PDF] U. Mosbauer, F. Ayuk, H. Schieder, M. Lioznov, A. R. Zander, and N. Kroger Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation Haematologica, February 1, 2007; 92(2): 275 - 276. [Abstract] [Full Text] [PDF] J-E Gottenberg, F Aucouturier, J Goetz, C Sordet, I Jahn, M Busson, J-M Cayuela, J Sibilia, and X Mariette Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome Ann Rheum Dis, January 1, 2007; 66(1): 23 - 27. [Abstract] [Full Text] [PDF] J. A. Katzmann, A. Dispenzieri, R. A. Kyle, M. R. Snyder, M. F. Plevak, D. R. Larson, R. S. Abraham, J. A. Lust, L. J. Melton III, and S. V. Rajkumar Elimination of the Need for Urine Studies in the Screening Algorithm for Monoclonal Gammopathies by Using Serum Immunofixation and Free Light Chain Assays Mayo Clin. Proc., December 1, 2006; 81(12): 1575 - 1578. [Abstract] [Full Text] [PDF] D. Dingli, R. A. Kyle, S. V. Rajkumar, G. S. Nowakowski, D. R. Larson, J. P. Bida, M. A. Gertz, T. M. Therneau, L. J. Melton III, A. Dispenzieri, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone Blood, September 15, 2006; 108(6): 1979 - 1983. [Abstract] [Full Text] [PDF] J. A. Katzmann Serum Free Light Chain Specificity and Sensitivity: A Reality Check Clin. Chem., September 1, 2006; 52(9): 1638 - 1639. [Full Text] [PDF] A. M. S. Muller, A. Geibel, H. P. H. Neumann, A. Kuhnemund, A. Schmitt-Graff, J. Bohm, and M. Engelhardt Primary (AL) Amyloidosis in Plasma Cell Disorders Oncologist, July 1, 2006; 11(7): 824 - 830. [Abstract] [Full Text] [PDF] J. M. Abadie and D. D. Bankson Assessment of serum free light chain assays for plasma cell disorder screening in a veterans affairs population. Ann. Clin. Lab. Sci., March 1, 2006; 36(2): 157 - 162. [Abstract] [Full Text] [PDF] T. D. Jaskowski, C. M. Litwin, and H. R. Hill Detection of {kappa} and {lambda} Light Chain Monoclonal Proteins in Human Serum: Automated Immunoassay versus Immunofixation Electrophoresis Clin. Vaccine Immunol., February 1, 2006; 13(2): 277 - 280. [Abstract] [Full Text] [PDF] M. R. Nowrousian, D. Brandhorst, C. Sammet, M. Kellert, R. Daniels, P. Schuett, M. Poser, S. Mueller, P. Ebeling, A. Welt, et al. Serum Free Light Chain Analysis and Urine Immunofixation Electrophoresis in Patients with Multiple Myeloma Clin. Cancer Res., December 15, 2005; 11(24): 8706 - 8714. [Abstract] [Full Text] [PDF] M. Q. Lacy, W. J. Hogan, M. A. Gertz, A. Dispenzieri, S. V. Rajkumar, S. Hayman, S. Kumar, M. R. Litzow, and A. L. Schroeter Successful Treatment of Scleromyxedema With Autologous Peripheral Blood Stem Cell Transplantation Arch Dermatol, October 1, 2005; 141(10): 1277 - 1282. [Abstract] [Full Text] [PDF] S. V. Rajkumar, R. A. Kyle, T. M. Therneau, L. J. Melton III, A. R. Bradwell, R. J. Clark, D. R. Larson, M. F. Plevak, A. Dispenzieri, and J. A. Katzmann Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance Blood, August 1, 2005; 106(3): 812 - 817. [Abstract] [Full Text] [PDF] I. Brockhurst, K. P. G. Harris, and C. S. Chapman Diagnosis and monitoring a case of light-chain deposition disease in the kidney using a new, sensitive immunoassay Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1251 - 1253. [Abstract] [Full Text] [PDF] A. R. Bradwell Serum Free Light Chain Measurements Move to Center Stage Clin. Chem., May 1, 2005; 51(5): 805 - 807. [Full Text] [PDF] J. A. Katzmann, R. S. Abraham, A. Dispenzieri, J. A. Lust, and R. A. Kyle Diagnostic Performance of Quantitative {kappa} and {lambda} Free Light Chain Assays in Clinical Practice Clin. Chem., May 1, 2005; 51(5): 878 - 881. [Abstract] [Full Text] [PDF] S. V. Rajkumar MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management Hematology, January 1, 2005; 2005(1): 340 - 345. [Abstract] [Full Text] [PDF] C. Decourt, H. R. Galea, C. Sirac, and M. Cogne Immunologic basis for the rare occurrence of true nonsecretory plasma cell dyscrasias J. Leukoc. Biol., September 1, 2004; 76(3): 528 - 536. [Abstract] [Full Text] [PDF] D. Coriu, K. Weaver, M. Schell, M. Eulitz, C. L. Murphy, D. T. Weiss, and A. Solomon A molecular basis for nonsecretory myeloma Blood, August 1, 2004; 104(3): 829 - 831. [Abstract] [Full Text] [PDF] J. R. Tate, D. Gill, R. Cobcroft, and P. E. Hickman Practical Considerations for the Measurement of Free Light Chains in Serum Clin. Chem., August 1, 2003; 49(8): 1252 - 1257. [Abstract] [Full Text] [PDF] S. Singhal, J. Mehta, B. M. Reilly, P. Clarke, and P. Nikolinakos Easy to See but Hard to Find N. Engl. J. Med., May 8, 2003; 348(19): 1931 - 1932. [Full Text] [PDF] J. A. Katzmann, R. J. Clark, R. S. Abraham, S. Bryant, J. F. Lymp, A. R. Bradwell, and R. A. Kyle Serum Reference Intervals and Diagnostic Ranges for Free {kappa} and Free {lambda} Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains Clin. Chem., September 1, 2002; 48(9): 1437 - 1444. [Abstract] [Full Text] [PDF] G. Marien, E. Oris, A. R. Bradwell, N. Blanckaert, and X. Bossuyt Detection of Monoclonal Proteins in Sera by Capillary Zone Electrophoresis and Free Light Chain Measurements Clin. Chem., September 1, 2002; 48(9): 1600 - 1601. [Full Text] [PDF] R. L. Comenzo and M. A. Gertz Autologous stem cell transplantation for primary systemic amyloidosis Blood, May 29, 2002; 99(12): 4276 - 4282. [Abstract] [Full Text] [PDF] M. S. Graziani, G. Merlini, A. R. Bradwell, M. T. Drayson, and G. P. Mead Measurement of Free Light Chains in Urine Drs. Bradwell, Drayson, and Mead respond: Clin. Chem., November 1, 2001; 47(11): 2069 - 2070. [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Drayson, M. Articles by Bradwell, A. R. Search for Related Content PubMed PubMed Citation Articles by Drayson, M. Articles by Bradwell, A. R. Related Collections Neoplasia Brief Reports Social Bookmarking                   What's this?

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020